Current Report Filing (8-k)
July 26 2017 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 26, 2017
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-36641
|
|
20-7273918
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
3 University Plaza Drive, Suite 320
|
|
Hackensack, NJ
|
07601
|
(Address of principal executive offices)
|
(Zip Code)
|
(201) 488-0460
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 1.01 Entry into a Material Definitive Agreement.
The
information contained in Item 5.02 below is incorporated by reference into this Item 1.01.
Item 5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Chief Executive Officer and President
On July 26, 2017
(the “Effective Date”), Brainstorm Cell Therapeutics Inc. (the “Company”) amended the terms of the employment
agreement between the Company and Chaim Lebovits, the Company’s President and Chief Executive Officer (the “Amendment”).
Pursuant to the Amendment, Mr. Lebovits will be paid an annual salary of $500,000 (the “Base Salary”). Mr. Lebovits
was granted on the Effective Date, and will also be eligible to receive in the future, an annual cash bonus equal to 50% of his
base salary, subject to his satisfaction of pre-established performance goals to be mutually agreed upon by the Board of Directors
of the Company and Mr. Lebovits. Performance shall be evaluated through a performance management framework and a bonus range based
on the target bonus. Mr. Lebovits will also receive other benefits that are generally made available to the Company’s employees.
Pursuant to the
Amendment, Mr. Lebovits received on July 26, 2017, and is entitled to receive on each anniversary thereafter, a grant of restricted
stock under the Company’s 2014 Global Share Option Plan (or any successor or other equity plan then maintained by the Company)
comprised of a number of shares of common stock of the Company, $0.00005 par value (“Common Stock”) with a fair market
value (determined based on the price of the Common Stock at the end of normal trading hours on the business day immediately preceding
the Effective Date according to Nasdaq) equal to 30% of Mr. Lebovits’ Base Salary (each, an “Equity Grant”).
Each Equity Grant shall vest as to twenty-five percent (25%) of the award on each of the first, second, third and fourth anniversary
of the date of grant, provided Mr. Lebovits remains continuously employed by the Company from the date of grant through each applicable
vesting date. Each Equity Grant shall be subject to accelerated vesting upon a Change of Control (as defined in the Amendment)
of the Company. In the event of Mr. Lebovits’ termination of employment, any portion of an Equity Grant that is not yet vested
(after taking into account any accelerated vesting) shall automatically be immediately forfeited to the Company, without the payment
of any consideration to the Executive.
Pursuant to the
Amendment, on July 26, 2017, Mr. Lebovits also received an option (the “Option”) under the Company’s 2014 Global
Share Option Plan to purchase up to an aggregate number of shares of Common Stock with a fair market value (as determined based
on the closing price of the Common Stock at the end of normal trading hours on the business day immediately preceding the date
of grant according to Nasdaq) of $200,000 on the Effective Date. The Option is fully vested and exercisable as of the date of grant
and shall remain exercisable until the 2
nd
anniversary of the date of grant, regardless of whether Mr. Lebovits
remains employed by the Company. The exercise price per share shall be equal to the fair market value on the date of grant (as
determined based on the price of the Common Stock immediately preceding normal trading hours on the date of grant according to
Nasdaq).
The Amendment contains termination provisions,
pursuant to which if the Company terminates the Employment Agreement or Mr. Lebovits’ employment without Cause (as defined
in the Amendment) or if Mr. Lebovits terminates the Employment Agreement or his employment thereunder with Good Reason (as defined
in the Amendment), the Company shall: (i) within 90 days pay Mr. Lebovits, as severance pay, a lump sum equal to six (6) months
of Base Salary (which shall increase to nine (9) months after the second anniversary of the Effective Date and twelve (12) months
after the third anniversary of the Effective Date) (provided Mr. Lebovits is actively employed by the Company on such dates) (the
“Payment Period”); (ii) pay Mr. Lebovits within 30 days of his termination of employment any bonus compensation that
Mr. Lebovits would be entitled to receive during the Payment Period in the absence of his termination without Cause or for Good
Reason; (iii) immediately vest such number of equity or equity based awards that would have vested during the six (6) months following
the date of termination of employment; and (iv) shall continue to provide to Mr. Lebovits health insurance benefits during the
Payment Period, unless otherwise provided by a subsequent employer. The foregoing severance payments are conditional upon Mr. Lebovits
executing a waiver and release in favor of the Company in a form reasonably acceptable to the Company.
Executive Vice President, Chief Business Officer
On July 26, 2017,
the Company approved an increase in the monthly gross base salary paid to Uri Yablonka, the Company’s Executive Vice President,
Chief Business Officer, to 41,000 NIS (approximately $11,600 per month).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRAINSTORM CELL THERAPEUTICS INC.
|
|
|
|
|
|
|
|
Date:
July 26, 2017
|
By:
|
/s/
Chaim Lebovits
|
|
|
|
Chaim
Lebovits
Chief Executive Officer and President
|
|
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024